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Innate recognition of apoptotic cells: novel apoptotic
cell-associated molecular patterns revealed by
crossreactivity of anti-LPS antibodies
I Tennant1, JD Pound1, LA Marr1, JJLP Willems1, S Petrova1, CA Ford1, M Paterson1, A Devitt1,2 and CD Gregory*,1
Cells dying by apoptosis are normally cleared by phagocytes through mechanisms that can suppress inflammation and
immunity. Molecules of the innate immune system, the pattern recognition receptors (PRRs), are able to interact not only with
conserved structures on microbes (pathogen-associated molecular patterns, PAMPs) but also with ligands displayed by
apoptotic cells. We reasoned that PRRs might therefore interact with structures on apoptotic cells – apoptotic cell-associated
molecular patterns (ACAMPs) – that are analogous to PAMPs. Here we show that certain monoclonal antibodies raised against
the prototypic PAMP, lipopolysaccharide (LPS), can crossreact with apoptotic cells. We demonstrate that one such antibody
interacts with a constitutively expressed intracellular protein, laminin-binding protein, which translocates to the cell surface
during apoptosis and can interact with cells expressing the prototypic PRR, mCD14 as well as with CD14-negative cells. Anti-LPS
cross reactive epitopes on apoptotic cells colocalised with annexin V- and C1q-binding sites on vesicular regions of apoptotic
cell surfaces and were released associated with apoptotic cell-derived microvesicles (MVs). These results confirm that apoptotic
cells and microbes can interact with the immune system through common elements and suggest that anti-PAMP antibodies
could be used strategically to characterise novel ACAMPs associated not only with apoptotic cells but also with derived MVs.
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Apoptotic cells undergo multiple surface changes, the most
renowned being the externalisation of the anionic phospholi-
pid, phosphatidylserine (PS).1 Profound alterations in plasma-
membrane topology also occur as a consequence of the
apoptosis programme, involving protein, carbohydrate and
nucleic acid moieties in addition to lipids (reviewed in Gregory
and Pound2). Gross changes in apoptotic cells include the
production of plasma-membrane-bound apoptotic bodies,
blebs and microvesicles (MVs),3,4 the latter serving functions
in intercellular communication, including chemoattraction and
activation of phagocytes.5–8 Taken together, these changes
permit a multitude of molecular interactions with phagocytes
triggering apoptotic cell engulfment and additional phagocyte
responses including immunomodulation. Detailed activities of
underlying receptor–ligand interactions participating in these
responses remain to be defined but it is clear that interference
with these processes can have pathological consequences
(see, Savill et al.,9 Lauber et al.,10 Ravichandran and Lorenz,11
Erwig and Henson,12 Elliott and Ravichandran13 and Gregory
and Pound,14 for reviews).
Many of the host proteins, including CD14, C1q and
collectins, that interact with apoptotic cells are molecules of
the innate immune system that were first known for their
involvement in host responses to microbes.15 The reverse
relationship is also proven: brain angiogenesis inhibitor 1,
characterised first in this context as a phagocyte receptor for
apoptotic cells, was recently also shown to function as an
immune receptor for bacterial binding and engulfment.16 All
these molecules fall into the category of the so-called ‘pattern
recognition receptors’ (PRRs) that interact with evolutionarily
conserved structures – ‘pathogen-associated molecular
patterns’ (PAMPs) – of microbes.17 For example, the
prototypic PRR, CD14, interacts with, and regulates proin-
flammatory host responses to, the prototypic PAMP, lipopo-
lysaccharide (LPS).18 Because of the involvement of PRRs in
the molecular interactions of phagocytes with apoptotic cells,
we and others previously suggested that apoptotic cells
express host equivalents of PAMPs termed ‘apoptotic
cell-associated molecular patterns’ (ACAMPs).19,20 This
notion predicts that ACAMPs share spatial similarities with
PAMPs that permit common PRR interactions. This led us to
hypothesise that some antibodies raised against PAMPs
could potentially crossreact with ACAMPs, thus providing an
opportunity to use antibody approaches to probe the
existence and nature of ACAMPs.
Here we test this hypothesis and demonstrate that certain
anti-LPS antibodies indeed show strong crossreactive binding
to apoptotic cells. We characterise a host epitope specified by
one of these antibodies, demonstrating (1) its association with
the intracellular protein, laminin-binding protein (LBP/p40), (2)
its exposure on apoptotic cells and (3) its ability to bind to cells
via both plasma-membrane CD14 (mCD14)-dependent and
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-independent mechanisms. These results provide further
evidence supporting the notion that apoptotic cells and
microbes share certain elements of immune recognition and
suggest a strategy whereby anti-PAMP antibodies can be
used to probe the molecular architecture of apoptotic cells and
of derived MVs.
Results
Certain monoclonal anti-LPS antibodies crossreact with
epitopes of apoptotic cells. To test the hypothesis that
certain anti-microbial antibodies can crossreact with
ACAMPs, endogenous molecules exposed by cells under-
going apoptosis, a panel of monoclonal antibodies (mAbs)
raised against LPS, was tested for reactivity towards
apoptotic, compared with viable, cells. Initial screening was
carried out by flow cytometry using a human lymphoma cell
line. Antibodies were selected according to their previously
characterised ability to react broadly across LPS species
(Table 1). Three (out of 13 anti-LPS mAbs tested) showed
clear binding to apoptotic, but not viable, cells (Figure 1a).
Immunoblotting of apoptotic lymphoma cell lysates indicated
that one of the three apoptotic cell-reactive anti-LPS mAbs,
15308, detected a protein-associated epitope, which, under
reducing conditions, ran at around 40 kDa (Figure 1b); the
remaining two apoptotic cell-reactive mAbs failed to detect
the same species (Figure 1b) or any other protein epitopes
under these conditions, indicating that additional, non-protein
ACAMPs may be identified using anti-LPS mAbs.
We sought to characterise further the cellular reactivity of
mAb 15308 and its cellular 40 kDa protein target. We first
determined whether the cellular target(s) of mAb 15308 are
conserved structures, as expected for ACAMPs,19,20 by
testing cells of different lineages and species. Figure 1c
shows flow cytometric analysis of mAb 15308 reactivity
towards primary human neutrophils and mouse thymoma
cells. Our further studies showed wide reactivity across
numerous cell lineages and species following induction of
apoptosis (Supplementary Table 1) with reactivity having
been found against all apoptotic cell types we have tested to
date. By immunoblotting we have not demonstrated any
qualitative changes in the antigen during apoptosis.
Specific binding of anti-LPS mAb 15308 to intracellular
cytoskeletal sites within viable cells and to surface buds
of apoptotic cells. To determine whether the cellular
targets of mAb 15308 were neoepitopes of apoptotic cells
or, alternatively, intracellular epitopes exposed during apop-
tosis, we analysed the binding of mAb 15308 to cells that had
been fixed and permeabilised in the absence of apoptosis
induction. Permeabilised lymphoma cells displayed strong
cytoplasmic mAb 15308 staining, comparable to that shown
by plasma membrane-compromised apoptotic cells
(Figure 2a and Supplementary Figure 1). To investigate the
pattern of cytoplasmic staining further, a range of adherent
cell lines were analysed in situ. Following fixation and
permeabilisation of growing monolayers, mAb 15308 was
found mainly to bind to intracytoplasmic filamentous struc-
tures (Figure 2b and c), colocalising with tubulin but not with
other cytoskeletal elements such as actin or cytokeratin-20
(Figure 2b). All cell lines tested showed similar filamentous
patterns of staining.
As surface architectural changes during apoptosis com-
monly result from translocation of molecules from intra- to
extracellular loci, we next determined whether cellular
epitopes of mAb 15308 were demonstrable on apoptotic cells
with intact plasma membranes. Flow cytometric analyses
initially suggested that this was not the case as only plasma
membrane-compromised, propidium iodide (PI)-positive
apoptosis-induced cells were reactive with mAb 15308. As
apoptotic populations contain fragile cells, which become
permeable during preparation for flow cytometry and/or during
the flow procedure (our unpublished observations), it
remained possible that mAb 15308 epitopes were displayed
on the surface of fragile apoptotic cells. To investigate this,
lymphoma cells and adherent cells (MCF-7) induced to
undergo apoptosis were analysed by confocal microscopy
following immunofluorescence and vital dye staining under
gentle, preparatory conditions (as opposed to the high-shear
steps required for flow cytometry). Strong mAb 15308
labelling could be observed on apoptosis-induced lymphoma
cells whose membranes excluded PI (Figure 3a). In some
cases, 15308 reactivity was seen to be associated with cells
displaying only very weak PI fluorescence, indicative of low
permeability and supporting the notion that mAb 15308
epitopes appeared on fragile apoptotic cells. Consistent with
this, using flow cytometry we could detect low levels of mAb
15308 binding to 10–15% of apoptotic BL cells that were
impermeable to PI (Supplementary Figure 2).
Given its strong intracellular reactivity as well as its
association with the cell surface during apoptosis, we wished
to determine whether mAb 15308 showed preference for
binding to immature glycoproteins via a carbohydrate ‘signa-
ture’ present at the surface of apoptotic cells.8 As such
immature glycoproteins are high in mannose residues, we
sought inhibition of binding of mAb 15308 by free mannose
and by the mannan-binding lectin, MBL. Free mannose
failed to affect mAb 15308 binding and MBL caused only
marginal inhibition (Supplementary Figure 3). Significantly,
MBL did not bind to surfaces of apoptotic cells tested
Table 1 Reported reactivities of commercially available crossreactive anti-LPS
mAbs used in these studies
mAb LPS specificity Species Isotype
15306 Shigella sonnei
Salmonella typhimurium
Serratia marcescens
Proteus mirabilis
Proteus vulgaris
Acinetobacter calcoaceticus
Mouse IgG2a
15308 Enterobacter aerogenes
Serratia marcescens
Proteus mirabilis
Acinetobacter calcoaceticus
Pseudomonas aeruginosa
Mouse IgG3
15174 Chlamydia trachomatis Mouse IgG2a
Antibodies were assessed by ELISA for binding to purified LPS. LPS of
Chlamydia trachomatis lacks the O-polysaccharide region most distal to lipid A.
Thus, although being marketed as anti-Chlamydia antibody, mAb 15174 was
chosen for its potential reactivity towards conserved core regions of LPS.
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(Supplementary Figure 2). These results indicate that mAb
15308 is unlikely to bind to carbohydrate signatures on
immature glycoproteins.
Further analyses revealed that mAb 15308 reactivity
was predominantly associated with vesicular structures:
small ‘buds’ or ‘blebs’ typical of the surface of apoptotic
cells (Figure 3b and c). Similar observations were made
with apoptotic lymphoma cells that grow in suspension
culture (Supplementary Figure 4). To analyse this further,
we investigated whether two additional known apoptotic
cell surface-binding proteins, annexin V (AxV) and C1q
associate with the same bleb-like surface structures as
mAb 15308. Confocal microscopic analysis revealed co-
distribution of mAb 15308 and AxV binding to isolated parts of
cell surfaces and vesicular structures on apoptotic cells with
intact plasma membranes (Figure 3d). Although both markers
were generally colocalised to the same regions of the cell
surface, coincident fluorescence was only occasionally
observed, indicating that mAb 15308 and AxV target distinct
molecular structures present in closely apposed regions of the
plasma membrane. Similarly, regions that bound mAb 15308
colocalised with C1q binding (Figure 3e).
Figure 1 Anti-LPS antibodies crossreact with multiple epitopes of apoptotic cells. (a) Flow cytometric profiles of MUTU I BL cells triggered into apoptosis by ionomycin and
stained using the indicated anti-LPS mAbs (white histograms), which were detected by fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse immunoglobulin G (IgG);
isotype control binding (g2a for mAbs 15174 and 15306, g3 for mAb 15308) is indicated by the black histograms. (b) Immunoblotted SDS-PAGE of MUTU I lysates probed with
the indicated anti-LPS mAbs or isotype controls demonstrating 40 kDa species specified by mAb 15308 but not 15174 or 15306. (c) Flow cytometric profiles of A1.1 hybridoma
cells (upper panels) and human neutrophils (lower panels) after induction of apoptosis by ionomycin or serum deprivation, respectively. Cells were stained with mAb 15308
detected as above; isotype control binding shown in black. Apoptotic and viable cells were discriminated by light scatter as described6
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These results show that the anti-LPS mAb 15308 binds to
intracellular, cytoskeleton-associated ligands in eukaryotic
cells and strongly suggest that translocation of these binding
sites to vesicular regions of the cell surface occurs during
apoptosis. We next determined whether mAb 15308-reactive
MVs were released from apoptotic cells.
MVs displaying protein ligands for mAb 15308 are
released from cells undergoing apoptosis. Before exam-
ining the MVs released from apoptotic cells for mAb 15308
reactivity, we sought further characterisation of the cellular
protein species identified by mAb 15308. Figure 4a illustrates
the relative reactivity of mAb 15308 associated with cellular
fractions isolated from human lymphoma cells by differential
centrifugation. Immunoblotting with mAb 15308 revealed
major differences among the four fractions, with the nuclear
fraction negative and most reactivity being detected as a
B40 kDa species found within the fraction (P1) containing
large organelles and protein complexes. Lower levels of the
40 kDa band were observed in the insoluble membrane
fraction (P2) and a faint higher-molecular-weight (B65 kDa)
species was seen in the soluble fraction.
Flow cytometric analysis of MVs isolated by ultracentrifuga-
tion of supernatants from lymphoma cells induced to undergo
apoptosis by UV irradiation indicated strong staining with mAb
15308 (Figure 4b) and immunoblotting confirmed the 40 kDa
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Figure 2 Anti-LPS antibody 15308 binding to intracellular epitopes of viable and apoptotic cells. (a) BL cells (MUTU I) were treated with ionomycin for 16 h to induce
apoptosis. Binding of the anti-LPS antibody, 15308, was visualised using goat anti-mouse secondary antibody labelled with Alexa Fluor-488 (green). Cells were counterstained
with the cell-impermeant dye, TO-PRO-3 (blue), for visualisation of nucleic acid and as a measure of membrane integrity. Unfixed, non-permeable viable cells were not stained
at all (lower cell, left and centre panels), whereas apoptotic cells, which rapidly became permeable, displayed green cytoplasmic staining (upper cell, left and centre panels);
the isotype-matched control antibody (g3) exhibited no staining (not shown). When fixed and permeabilised, cells also exhibited cytoplasmic staining with mAb 15308 (green)
whether viable or apoptotic (right panel). Viable cells displayed a large rounded nucleus (V, right panel), whereas the nuclei of apoptotic cells (arrow) were condensed and
fragmented. (b) mAb 15308 associates with microtubules in adherent cell lines. Fixed and permeabilised A549 cells were double-stained with mAb 15308 (visualised green)
and cytoskeletal markers (visualised red): anti-tubulin antibody (left), actin-binding phalloidin (centre) and cytokeratin 20 (right). (c) Filamentous patterns of 15308 staining in
MCF-7 (left) and COS-1 (right) cells
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species associated with these MVs (Figure 4c). MVs from
untreated lymphoma cells also stained positively for mAb
15308 but at lower levels than those undergoing apoptosis
(Figure 4b), possibly reflecting the low level of spontaneous
apoptosis in the untreated cells. To investigate further the
‘15308 phenotype’ of MVs produced by apoptotic cells, we
induced a lymphoma line, BL2, into apoptosis using staur-
osporine and analysed the resultant MVs, comparing them
with MVs from BL2-Bcl-2 cells, which were largely protected
from staurosporine-induced apoptosis. We observed an
increase in MV production over time by apoptotic BL2 cells
but not by the apoptosis-protected BL2-Bcl-2 cells (Figure 4d).
It is worth noting that the low-level production of MVs by
BL2-Bcl-2 cells may relate to the low-level apoptosis induced
in these cells (Figure 4) as well as representing MVs from
viable cells. As shown in Figure 4e, in addition to lower levels
of MVs being released from Bcl-2-protected BL2 cells, their
capacity to bind mAb 15308 was markedly lower (B40% were
15308 positive) than the MVs released from overtly apoptotic
BL2 cells (B70% 15308 positive). These results indicate that
mAb 15308 binding sites are preferentially released in
association with MVs produced by apoptotic cells.
Cellular targets of mAb 15308 include LBP/p40. MALDI-
TOF-mass spectrometry was used to characterise further the
main (B40 kDa) protein species observed in immunoblots
reactive with mAb 15308. Three polypeptide species were
initially identified: b-actin, LBP/p40 and the septin, NEDD5
(neuronally expressed, developmentally downregulated-5;
Supplementary Figure 5). b-Actin was not considered as a
candidate mAb 15308-reactive protein as (a) distinct patterns
of intracellular localisation were seen when phalloidin
staining was compared directly with immunocytochemical
labelling by mAb 15308 (Figure 2b), and (b) immunoblotting
of fractionated cell lysates had shown actin to be present in
different relative proportions to the mAb 15308-binding
species (Figure 4a).
We next undertook molecular cloning of LBP/p40 and
NEDD5 using mRNA from lymphoma cells. Lysates of
HEK293T cells expressing exogenous V5-tagged LBP/p40
were immunoblotted both with a V5-specific mAb and with
mAb 15308. Exogenously expressed LBP/p40 was observed
as two species of B40 kDa and of 50–70 kDa as detected
using the anti-V5 mAb antibody (Figure 5a, left). This is
consistent with both the faint band seen in fraction S of
lymphoma cell lysates (Figure 4a) and the previously reported
67 kDa form of this protein.21 Lysates of cells transfected with
V5-tagged exogenous NEDD5 displayed the NEDD5 poly-
peptide (B42 kDa) in immunoblots using anti-V5 but mAb
15308 failed to bind NEDD5 (Figure 5b). Furthermore, mAb
15308 failed to detect any bands in addition to the
endogenous 40 kDa (LBP/p40) species found in lysates of
mock-transfected cells.
To determine whether the intracellular distribution of the
exogenous LBP/p40 reflected that of the reactivity of mAb
15308, immunofluorescence double-labelling of MCF-7 cells
by anti-V5 and 15308 mAbs was performed. Anti-V5 and mAb
15308 labelling were generally independent, with only
occasional coincident fluorescence, especially in the peri-
nuclear region (Figure 5c). Similar results were seen using a
GFP-LBP/p40 construct in place of the V5 expression system
(not shown). It seems likely that mAb 15308 binds multiple
intracellular epitopes and that only a small subset is
represented by LBP/p40. Notably, exogenous LBP/p40
expression failed to generate detectable increases in mAb
15308 binding.
Given our earlier observations that mAb 15308 reactivity
could be detected on the surface of apoptotic cells, we next
15308 (green) + PI (red) 15308 (green)
15308 (red) + Annexin V (green) 15308 (red) +
C1q (green)
Figure 3 Appearance of mAb 15308 reactivity on cell surface buds or blebs
during apoptosis. (a) Confocal microscopy of exposure of mAb 15308 epitopes at
the surface of MUTU I BL cells induced to undergo apoptosis with ionomycin.
Binding of mAb 15308 was visualised using secondary antibody labelled with Alexa
Fluor-488 (green); plasma membrane integrity was monitored using PI (red). Note
that mAb 15308 binds to cells excluding PI as well as to those displaying weak or
strong PI staining. (b) Microscopic analysis of mAb 15308 reactivity associated with
surface buds (arrowheads) of PI-negative MCF-7 cells triggered to undergo
apoptosis with etoposide. Top panel shows surface buds under transmitted light
differential interference contrast. (c) Closer inspection by confocal microscopy of
surface reactivity of two separate etoposide-treated MCF-7 cells. (d) Confocal
fluorescence images of surface 15308 reactivity (visualised using secondary
antibody labelled with Alexa Fluor-568, red) colocalised with AxV binding sites (most
likely PS) visualised with streptavidin-labelled Alexa Fluor-488, green) on etoposide-
treated MCF-7 cells. (e) Confocal microscopic analysis of mAb 15308 reactivity (red)
and C1q binding (biotinylated C1q visualised with streptavidin–Alexa Fluor-488,
green) at the surface of MUTU I BL cells induced to undergo apoptosis with
ionomycin. No staining was observed when biotinylated IgG1 was used instead of
C1q or when isotype control replaced mAb 15308 (not shown). Membrane integrity
was monitored by exclusion of TO-PRO-3, which fluoresced blue in permeable cells
(not shown). The upper panel is a bright field image overlaid with the fluorescence
associated with a mid-way Z-section, and the lower panel shows total cell-
associated fluorescence
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sought surface expression of exogenous LBP/p40 during
apoptosis. Following induction of exogenous V5-tagged LBP/
p40-expressing MCF-7 cells into apoptosis, it was possible to
detect by confocal microscopy small amounts of the V5
epitope at the surface of cells with intact plasma membranes
(Figure 5d). Perhaps unsurprisingly given the observations
above (Figure 5c), such display of exogenously exposed LBP/
p40 was a rare event, observed ono2% of the cells.
These results indicate that LBP/p40 is a component, albeit
minor, of the cellular crossreactivity of mAb 15308 and
demonstrate that this protein is translocated from its
intracellular location in viable cells to be exposed on the
surface of cells undergoing apoptosis.
Interaction of recombinant LBP/p40 with cells via
mCD14-dependent and -independent mechanisms. To
investigate further the possibility that LBP/p40 constitutes an
ACAMP, we next determined its capacity for PRR interaction,
nominating mCD14, the prototypic PRR as a candidate. For
these studies, recombinant LBP/p40 was produced in
Escherichia coli, in human K562 and MCF-7 cells and in
insect sf9 cells. Immunoblots of transformed E. coli lysates
and of derived nickel affinity-purified preparations probed
with mAb 15308 revealed three protein species that were
absent from non-transformed lysates, the main bands being
B40 andB65 kDa (Figure 6a and b). The latter species were
readily detected with the anti-V5 mAb and also by an
antibody against the 67 kDa laminin receptor (Lam-R;
Figure 6b). These results indicate that eukaryotic processing
is unnecessary for binding of LBP/p40 to mAb 15308.
Recombinant LBP/p40 purified from MCF-7 and K562
transfectants displayed similar major species of B40 and
50–70 kDa (Figure 6b), although K562 material was only
visible in blots using the sensitive anti-V5 antibody, reflecting
the relatively low level of recombinant protein produced by
these cells (Supplementary Figure 6). Using the insect
system, high levels of expression were obtained and
mAb 15308 reactivity was almost entirely associated in
immunoblots of cell lysates or nickel-purified protein with the
50–70 kDa species (Figure 6c), although a B40 kDa band
could also be observed upon overexposure (not shown).
Recombinant LBP/p40 proteins from bacterial, human and
insect cells were tested in flow cytometric assays for their
ability to bind to K562 cells, which are constitutively CD14
negative, and to K562 transfectants stably expressing mCD14
(Figures 6d–f). Recombinant protein binding to cells was
visualised by indirect immunofluorescence using anti-V5 mAb
as primary. Preferential binding of bacterial LBP/p40 prepara-
tions to mCD14-expressing cells was observed (Figure 6d).
Given the role of CD14 as an LPS receptor, it is conceivable
that LPS contamination of the bacterial LBP/p40 preparations
aided mCD14 binding. However, similar concentrations of
LPS found in preparations of LBP/p40 derived from bacteria
failed to enhance binding of eukaryotic, LPS-free preparations
either secreted by K562 transfectants or purified from lysates
of MCF-7 transfectants (Figure 6e). While it is possible that
the levels of purified LBP/p40 in these preparations were too
low for detection in these preparations, this seems unlikely as
binding activity (albeit low) was consistently observed,
especially with the K562-derived protein (Figure 6e, bottom
right). When higher concentrations of eukaryotic protein were
tested, as was possible using the insect expression system
(Figure 6f), significant levels of binding to both mCD14-
negative and -positive cells were observed. Differences in
binding patterns between recombinant LBP/p40 produced in
prokaryotic versus different eukaryotic cells may be due to the
differential processing of the protein in these different
contexts.
These results indicate that, while recombinant LBP/p40 (at
least when produced in bacteria) may show propensity to bind
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Figure 4 mAb 15308 reveals a 40 kDa protein associated with apoptotic cell-derived microvesicles. (a) SDS-PAGE and immunoblots of lysate from MUTU I BL cells
fractionated by sequential centrifugation into 1000 g (N), 27 000 g (P1), 100 000 g (P2) pellets and remaining supernatant (S). (b) Flow cytometric analysis of mAb
15308 reactivity with MV produced by MUTU I BL cells with (left panel) and without (right) induction of apoptosis by UV irradiation for 16 h. Black histogram indicates isotype
control binding. (c) Immunoblotting of mAb 15308 reactivity with MVs produced by MUTU I BL cells after induction of apoptosis by UV irradiation for 16 h. (d) Quantification by
protein assay of MVs liberated by 10 106 BL2 cells and Bcl-2-overexpressing BL2 cells (BL2-Bcl-2) following induction of apoptosis by staurosporine. One-tailed unpaired
Mann–Whitney test; *Pr0.05. By 4 h, 470% of staurosporine-treated BL2 cells bound AxV, compared with 5–25% BL2-Bcl-2 cells. (e) Flow cytometric analyses of mAb
15308-stained MVs isolated from BL2 and BL2-Bcl-2 cells following apoptosis induction by staurosporine for 3 h. Histograms of representative samples of MVs isolated from
3 h staurosporine-treated BL2 (left panel) and BL2-Bcl-2 (middle) cells are shown. Percentages of 15308-positive MVs are indicated on the histograms and mean
percentages±S.E.M (n¼ 3 independent experiments for each cell type) are shown (right). One-tailed unpaired Mann–Whitney test; *Pr0.05
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Figure 5 Detection of LBP/p40 by mAb 15308 and expression of exogenous LBP/p40 on the surface of apoptotic cells. (a) Exogenous expression of the LBP/p40 cDNA
(pcDNA3.1D/LBP/p40-V5-His) in lysates from transiently transfected HEK293T cells (lane: p40) and detection of 40 and 50–70 kDa species by anti-V5 antibody and by mAb 15308
but not by isotype control antibody (g3) or anti-actin antibody. Lysates from mock-transfected cells are shown for comparison (lane: M). (b) Exogenous expression of the NEDD5
cDNA (pcDNA3.1D/NEDD5-V5-His) in lysates from transiently transfected HEK293T cells (lane: N5) and detection by anti-V5 antibody but not by mAb 15308. NEDD5 was not
detected in mock-transfected cells (lane: M) and mAb 15308 detected endogenous 40 kDa bands in lysates from both NEDD5- and mock-transfected cells. Note that the differences
in signal intensity between anti-V5 and mAb 15308 can be explained by the exquisitely high affinity of anti-V5 for its epitope. (c) Immunofluorescence microscopic analysis of MCF-7
cells transiently transfected with pcDNA3.1D/LBP/p40-V5-His and double-stained with anti-V5 followed by Alexa Fluor-488-tagged secondary antibody (green, left panel), and mAb
15308 followed by Alexa Fluor 568-tagged secondary antibody (red, centre panel). Right panel shows overlay of red/green fluorescence and arrows indicate an example of an area
where coincident fluorescence was observed. (d) Surface exposure of exogenous V5-tagged LBP/p40 stably expressed in MCF-7 cells. Confocal microscopy of MCF-7/V5-LBP/
p40 transfectants after 48 h etoposide treatment. Exogenous LBP/p40 was detected using anti-V5 and secondary antibody tagged with Alexa Fluor-488 (green). Plasma membrane
integrity was monitored by PI (red) exclusion. Z-sections of rare cells revealed the presence of the V5 epitope on surface blebs with plasma membranes intact (arrows, upper
panels) as opposed to membrane compromised cells (arrows, lower panels), which stained green throughout the cell and were positive for PI
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mCD14, this is not an absolute requirement and CD14-
independent binding pathways are also evident.
Discussion
To clear apoptotic cells efficiently, the innate immune system
deploys multiple receptors, including PRRs that are renowned
for their roles in host responses to microbes. Notwithstanding
the well-established, opposed inflammatory responses of the
host to apoptotic cells versus microbial invaders, the use of
common receptors to engage with apoptotic cell- and
pathogen-borne ligands has suggested that molecular pat-
terns sharing three-dimensional structure are displayed by
both microbes and apoptotic cells, leading to the proposed
parallels between PAMPs and ACAMPs. Here we investi-
gated a natural extension of this concept of innate immunity,
rationalising that common structural features of PAMPs and
ACAMPs should be definable on the basis of crossreactivity of
derivatives of adaptive immune receptors, antibodies. We
predicted that certain antibodies raised against PAMPs would
crossreact with ACAMPs. The results of these studies show
that, in a small sample of anti-LPS mAbs, just under a quarter
crossreacted with cells undergoing apoptosis. The findings of
the initial screening suggested that such crossreactivities
encompassed both protein and non-protein molecular spe-
cies, including a cytoskeleton-associated protein, LBP/p40,
which carries epitopes recognised by the anti-LPS mAb,
15308.
An underlying principle of apoptosis – the translocation of
intracellular structures to the dying-cell surface – has been
demonstrated for a variety of molecules, most famously PS,
which flops from the inner to the outer plasma membrane
leaflet and engages with phagocytes via multiple PS
receptors.1,22–26 Nucleic acid27 and a diverse range of
proteins, including calreticulin,28 annexin 1,29,30 the large
subunit of the eukaryotic translation initiation factor 331 and
%
 o
f M
ax
im
um
 
anti-V5 + 
GAM-FITC
LBP/p40
anti-V5 + 
GAM-FITC
- LPS
+ LPS Fluorescence intensity
CD14-ve
CD14+ve
CD14+ve
%
 o
f M
ax
im
um
Fluorescence intensity
CD14-ve
%
 o
f M
ax
im
um
sf9 cell
lysates
15308 Lam-R anti-V5 15308
NI p40 p40/F
35
50
75
35
50
75
K5
62
M
CF
-7
E.
 c
ol
i
K5
62
M
CF
-7
E.
 c
ol
i
K5
62
M
CF
-7
E.
 c
ol
i
35
50
75
p40 NT
15308
CD14+ve CD14-ve
M
CF-7
K562
Fluorescence intensity
GAM-FITC
63D3
rLBP + anti-V5 + GAM-FITC
rLBP + GAM-FITC
anti-V5 + GAM-FITC
Figure 6 Production of recombinant LBP/p40 in different expression systems and reactivity with mCD14. (a) Presence of recombinant protein in LBP/p40
(p40)-transformed or non-transformed (NT) E. coli lysates was detected by probing immunoblots of total protein with mAb 15308. (b) LBP/p40 was expressed as an
intracellular protein in E. coli and MCF-7 cells or as a secreted protein in K562 cells. Immunoblots of nickel affinity-purified LBP/p40 preparations were probed with mAb 15308
(left panel), Lam-R (a commercially available anti-LBP/p40 antibody; middle panel) or anti-V5 (right panel). (c) Expression of recombinant LBP/p40 in baculovirus-infected sf9
insect cells detected by probing immunoblots of total protein from non-infected (NI) or recombinant-LBP/p40 (p40) baculovirus-infected cells with mAb 15308. Nickel metal
affinity-purified LBP/p40 (p40/F) is shown for comparison. In all immunoblots, equivalent amounts of total protein were included in each lane. (d) Flow cytometric analysis of
binding of purified preparations of recombinant LBP/p40 produced in E. coli to wild-type K562 cells (CD14 negative) or to K562 cells overexpressing CD14 (CD14 positive).
Bound recombinant protein was detected with anti-V5 antibody followed by anti-mouse secondary antibody labelled with FITC (GAM-FITC). (e) Failure of contaminating LPS to
mediate binding of recombinant LBP/p40 to CD14. Purified preparations of LPS-free, eukaryotic LBP/p40, prepared from MCF-7 or K562 expression systems were incubated
with CD14 negative or CD14 positive K562 cells and binding visualised as in (d). Binding of recombinant protein preparations were assessed in the presence or absence of
LPS in concentration equivalent to that found contaminating the bacterial preparation used in (d). (f) LBP/p40 derived from a baculovirus insect expression system fails to
bind preferentially to mCD14-expressing cells. Purified preparations of insect-derived LBP/p40 were tested for binding to mCD14 negative and positive cells as described for
(d) and (e). Numbers at the top right of each histogram represent the total protein concentration of recombinant LBP/p40 incubated with cells (mg/ml). Surface expression of
CD14 in K562 (d–f) cells was monitored by staining with mAb 63D3 (anti-CD14)
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the long pentraxin PTX3,32 have also been shown to move to
the surface of apoptotic cells from intracellular locations via as
yet unknown mechanisms to facilitate phagocytic clearance.
Recently in Drosophila, two proteins of the endoplasmic
reticulum, Pretaporter and DmCaBP1, have been observed to
become externalised in apoptosis aiding phagocytosis
mediated by Draper, a fly hemocyte receptor for apoptotic
cells that is homologous to CED-1.33,34 We established that
LBP/p40 translocates from its intracellular location to the
plasma membrane surface during apoptosis. In light of our
observations (e.g. Figure 5c) mAb 15308-reactive epitopes
are most probably not limited to LBP/p40. Regardless of their
molecular species, however, they associate with exposed PS
and C1q binding sites, appear on the blebs of apoptotic cells
and constitute components of released MVs. As changes in
plasma membrane topology associated with apoptosis are
likely to form the molecular basis for establishing the apoptotic
cell side of the phagocytic synapse,9,35,36 we speculate that
ACAMPs, as defined according to the principle demonstrated
here, are present within an assortment of molecular structures
that, together with additional changes such as PS exposure,
endow the apoptotic cell with discrete regions through which
to interact effectively with phagocyte receptors. Concentrating
here on mCD14, a well-defined PRR that interacts both with
LPS and with apoptotic cells, our results were unable to show,
at least for eukaryotic cell-derived LBP/p40, preferential
binding to this receptor. A further PRR, MBL, also failed to
interact with surface ACAMPs (Supplementary Figure 2). It
will be important to determine not only the PRR preferences of
‘LPS-like’ ACAMPs but also their functional attributes in
engagement with phagocytes. In relation to the latter, we
undertook preliminary investigations of possible involvement
of LPS-like ACAMPs in interactions between apoptotic cells
and macrophages under conditions in which a role for CD14
was demonstrable using an antagonistic CD14 mAb. How-
ever, none of the three crossreactive anti-LPS mAbs tested
here was observed to antagonise macrophage/apoptotic cell
interactions in these assays (Supplementary Figure 7).
Further work is warranted to clarify functional effects of
LPS-like ACAMPs.
In conclusion, the present work demonstrates that anti-
PAMP mAbs can be used to probe the molecular architecture
of the apoptotic cell surface, which remains poorly defined to
date. Although we have restricted these initial investigations
to anti-LPS antibodies, we believe that more widespread
cross-reactivities with ACAMPs defined by antibodies speci-
fying alternative PAMPs will be defined in the future. We
propose that anti-PAMP mAbs constitute useful and readily
accessible tools, which will help not only to improve our
understanding of the structural and functional properties of
apoptotic cell surfaces, but also to accelerate the acquisition
of much-needed knowledge of the phenotypes and functions
of apoptotic cell-derived MVs. Although our present reasoning
favours PAMP-like epitopes as ultimately activating non-
phlogistic responses to apoptotic cells in the ACAMPs model,
it is also conceivable that such epitopes could play roles in
proinflammatory, immunogenic responses to apoptosis,
thereby behaving as DAMPs – damage-associated molecular
patterns.37,38 Such responses may mirror the classical
proinflammatory effects of PAMPs acting via PRRs.
Materials and Methods
Cells. Adherent cells (MCF-7, A549, COS-1 and 293T) were cultured in
Dulbecco’s modified Eagle’s medium (Invitrogen, Paisley, UK) supplemented with
10% (v/v) Serum Supreme (Lonza, Slough, UK) or 10% foetal bovine serum (PAA
Laboratories Ltd, Yeovil, UK), 100 U/ml penicillin (PAA Laboratories), 100mg/ml
streptomycin (PAA Laboratories) and 2 mM L-glutamine (PAA Laboratories).
Suspension cells (MUTU I, BL2, K562, A1.1 and BJAB) were maintained in RPMI
1640 (Invitrogen) supplemented with 10% (v/v) Serum Supreme, 100 U/ml
penicillin, 100mg/ml streptomycin and 2 mM L-glutamine. Primary polymorpho-
nuclear leucocytes were isolated as described.39 Sf9 insect cells were cultured at
27 1C in Sf-900 II medium (Invitrogen).
Antibodies and Proteins. Antibodies were from QED Biosciences (San
Diego, CA, USA; accession numbers 15174, 15306 and 15308), Invitrogen (anti-
V5; goat-anti-mouse IgG Alexa Fluor conjugates), Sigma-Aldrich (Poole, UK; goat-
anti-mouse IgG-FITC; isotype controls IgG1, IgG2a and IgG3; anti-b-actin
(AC15)), AbD Serotec (Kidlington, UK; IgG3 isotype control), Neomarkers
(Runcorn, UK; anti-b-tubulin (DM-1B)), DAKO M7901 (Carpinteria, CA, USA; anti-
cytokeratin-20 (KS20.8)), Santa Cruz Biotechnology (Santa Cruz, CA, USA; LamR
(F-18)) and Amersham Biosciences (Little Chalfont, UK; goat-anti-mouse IgG-
HRP). Additional anti-LPS antibodies (non-crossreactive with apoptotic cells) were
produced in-house by Universities of Birmingham and Edinburgh (UK). 63D3 anti-
CD14 was obtained as described.40 Oligomeric recombinant mannan binding
lectin (rMBL), MW 700 kDa, was a generous gift from Prof. JC Jensenius
University of Aarhus (Aarhus, Denmark) and was biotinylated by standard
methods. Alexa Fluor-488-conjugated streptavidin was from Invitrogen.
Apoptosis induction and measurement. Apoptosis was induced by
1mM ionomycin (Calbiochem, San Diego, CA, USA) or UV-B irradiation (200 mJ/
cm2) for up to 16 h for MUTU I, 1mM staurosporine (Calbiochem) for BL2 and BL2-
Bcl-2 cells, 100 mM etoposide (Sigma) for MCF-7 for 48–72 h, 125 ng/ml TRAIL
(Affiniti Research Products, Exeter, UK) with 10 mg/ml cycloheximide (Sigma) for
K562 for 8 h, or aged in the absence of serum (PMNs, 16–24 h). Levels of
apoptosis were measured using TO-PRO-3 (3mM; Invitrogen) by assessing
condensation of chromatin by fluorescence microscopy (Axioskop 2; Zeiss,
Feldbach, Switzerland) or by flow cytometric analysis of Alexa Fluor-488
conjugated AxV (Invitrogen) binding and PI (Sigma) uptake as described.6
Molecular cloning, recombinant protein expression and
purification. Reverse transcriptase primers were designed and PCR was
used to amplify the complete coding sequence of LBP/p4041 and NEDD542
(accession numbers X61156.1 and BC014455.1, respectively) from mRNA
prepared from MUTU I cells using TRI reagent. Primer sequences, designed using
the Amplify 1.0 software (University of Winconsin, WI, USA), were forward,
50-CACCATGTCCGGAGCCCTTGAT-30 and reverse, 50-AGACCAGTCAGTGGT
TGCTCCTAC30-for LBP/p40; and forward, 50-CACCATGTCTAAGCAACAGCC
AACTCAG-30 and reverse, 50-CACGTGGTGCCCGAGAGCCCCG-30 for NEDD5.
DNA sequences were amplified using Pfu Polymerase (Qiagen, Crawley, UK).
Blunt-ended PCR products were cloned into pcDNA3.1D/V5-His-TOPO vector
using the pcDNA3.1 Directional TOPO % expression kit (Invitrogen) using the
manufacturer’s protocol. HEK293T, MCF7 and K562 cells were transfected by
electroporation. DNA encoding LBP/p40 was subcloned into pTrcHis2C
(Invitrogen) for subsequent expression in E. coli by IPTG. LBP/p40 was
expressed in Spodeoptera frugiperda Sf9 insect cells using the Bac-to-Bac
expression system (Invitrogen). His-tagged proteins were purified by His-Trap
columns (Amersham Biosciences) and Fc-fusion proteins by Hitrap protein G
column (Amersham Biosciences), and fractions containing eluted protein were
identified using a modified Bradford Reagent assay (Bio-Rad Laboratories,
Hercules, CA, USA) according to the manufacturer’s instructions.
MV isolation. Cells were cultured at 3 106/ml (for flow cytometry
analysis, unless otherwise stated) or 10 106/ml (for immunoblotting) in
0.22mm filtered RPMI 1640 supplemented with 2 mM L-glutamine, 100 U/ml
penicillin and 100mg/ml streptomycin, with or without 0.5% bovine serum albumin
(low endotoxin; Sigma-Aldrich). Apoptosis was induced by exposure of cells to
1mM staurosporine. MVs were isolated by sequential centrifugation; cell culture
supernatants were obtained by centrifugation at 300 g for 5 min followed by
750 g for 10 min to remove cells and large debris, respectively. Supernatants
were then centrifuged at either 14 000 g for 5 min (for flow cytometry analysis,
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unless otherwise stated) or at 100 000 g for 30 min (for immunoblotting) at
41C and resuspended in 0.22 mm double-filtered Dulbecco’s PBS without
Ca2þ and Mg2þ (PAA). Quantification of MV proteins was by the Bradford
method (Bio-Rad).
Flow cytometry. Fluorescence staining and flow cytometric analysis of cells
was carried out as described.6 Binding of biotinylated rMBL was detected using
Alexa Fluor-488-conjugated streptavidin. For MV staining, MVs from 6 106 cells
were isolated as described above. Washing and incubation with antibodies was in
0.22mm filtered PBS containing 5% normal goat serum (Biosera, Ringmer, UK) at
14 000 g. After two washes, MVs were stained with primary antibody or isotype
control for 40 min at 4 1C. After washing two times, MVs were stained with Alexa
Fluor-488-conjugated goat anti-mouse IgG secondary antibody for 15 min at 4 1C,
followed by two washes and resuspension in 400ml washing buffer for analysis.
Cell and MV samples were analysed using an Epics-XL-MCL flow cytometer
(Beckman Coulter, High Wycombe, UK). Electronic gates for MVs were set using
fluorescence-labelled 1mm beads (Polysciences, Eppelheim, Germany). Analysis
was performed using FlowJo (Treestar Inc., Ashland, OR, USA).
Immunofluorescence microscopy. Cells were seeded onto 4-well
Teflon-coated slides 24 h before analysis. Cells were fixed and permeabilized in
PBS containing 3% formaldehyde/5% sucrose/0.2% Triton X-100 (Bio-Rad).
Excess free aldehyde groups were quenched with 50 mM NH4Cl in PBS. Cells
were sequentially incubated with specified primary followed by conjugated
secondary antibody. Slides were air-dried and mounted using Mowiol
(Calbiochem) and viewed using confocal laser scanning microscope systems
(Leica Microsystems, Milton Keynes, UK and Zeiss) equipped with Ti:Sapphire
lasers. Formal microscopic quantification was not carried out prospectively
throughout these studies but when scored, the incidences of mAb 15308-positive
cells as a percentage of the total were found to be closely equivalent to those
reported by flow cytometry (data not shown).
Immunoblotting. Cell lysates were prepared by sonication in 10 mM HEPES
(Sigma), pH 7.4, 1 mM EDTA and 1% Triton X-100 with mammalian protease
inhibitor cocktail (Sigma) and used in immunoblotting as described.6
Mass spectrometry. Protein bands of interest were excised from SDS-
PAGE gels and analysed by peptide mass fingerprinting by MALDI-TOF Mass
Spectrometry (Applied Biosystems, Warrington, UK; Voyager DE STR MALDI-TOF
mass spectrometer). These masses were submitted to database search engines
(SwissProt and Mascott) to identify a list of potential identities.
Statistics. A one-tailed unpaired Mann–Whitney test was applied to calculate
P-values. All statistics were performed using the GraphPad Prism 5 Software
(GraphPad Software, San Diego, CA, USA).
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